Methods to accelerate antibody diversification

Patent metadata

Field	Value
Publication number	US-10308930-B2
Application number	US-201515514052-A
Country	US
Kind code	B2
Filing date	Nov 5, 2015
Priority date	Nov 6, 2014
Publication date	Jun 4, 2019
Grant date	Jun 4, 2019

Abstract

Methods for increasing somatic hypermutation of antibodies, especially in vitro expression of an isolated retroviral protein in an isolated mammalian immunoglobulin-producing cell, are provided.

First claim

What is claimed is:

1. A method of increasing somatic hypermutation of an immunoglobulin loci comprising effecting expression of a Tat protein in (i) an isolated mammalian immunoglobulin-producing cell, or (ii) an isolated immunoglobulin-producing cell of a cell line derived from a mammal, in an amount effective to increase somatic hypermutation of an immunoglobulin loci.

2. The method of claim 1 , wherein expression is effected in an isolated mammalian immunoglobulin-producing B cell.

3. The method of claim 1 , wherein expression is effected in the isolated immunoglobulin-producing cell of a cell line derived from a mammal.

4. The method of claim 3 , wherein the isolated immunoglobulin-producing cell of a cell line derived from a mammal is a cell that does not constitutively express immunoglobulins, but which has been genetically engineered to express immunoglobulins.

5. The method of claim 3 , wherein the isolated immunoglobulin-producing cell of a cell line derived from a mammal is a Ramos cell line.

6. The method of claim 1 , wherein the isolated immunoglobulin-producing cell of a cell line derived from a mammal is a hybridoma.

7. The method of claim 1 , wherein the cell secretes immunoglobulins.

8. The method of claim 1 , wherein the cell expresses immunoglobulins on a cell surface thereof.

9. The method of claim 1 , wherein the expression of the isolated exogenous protein is of a retroviral protein in the cell is effected by contacting the cell with a vector encoding the isolated retroviral protein.

10. The method of claim 1 , wherein the isolated retroviral protein is an HIV-2 Tat protein.

11. The method of claim 9 , wherein the vector is a lentiviral vector.

12. The method of claim 9 , wherein the vector is an adenoviral vector.

13. The method of claim 1 , wherein the expression of the HIV Tat protein in the cell is effected by contacting the cell with a pCDNA-tat eukaryotic expression vector encoding the exogenous HIV Tat protein.

14. The method of claim 1 , further comprising recovering one or more immunoglobulins produced by the cell of (i) or (ii) subsequent to effecting expression of the isolated exogenous protein therein.

15. The method of claim 14 , further comprising screening the one or more immunoglobulins for activity against a predetermined antigen.

16. The method of claim 1 , further comprising reducing expression of Spt5 in the cell of (i) by contacting the cell with a RNAi nucleic acid directed to Spt5.

17. The method of claim 16 , wherein the RNAi nucleic acid directed to Spt5 is a siRNA or an shRNA.

18. The method of claim 17 , wherein the RNAi nucleic acid is an shRNA delivered by a vector.

Assignees

• Albert Einstein College Medicine Inc
• Albert Einstein College Medicine

Inventors

• Wang Xiaohua
• Scharff Matthew

Classifications

• C12N15/86

  Viral vectors · CPC title

• C12N2310/531

  Stem-loop; Hairpin · CPC title

• C12N15/1024 Primary

  In vivo mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair · CPC title

• C12N2740/15043

  viral genome or elements thereof as genetic vector · CPC title

• C07K2319/80

  containing a DNA binding domain, e.g. Lacl or Tet-repressor · CPC title